-
Regulation and response to drug shortages in China
PharmaSources/zhulikou431
June 12, 2023
China's regulation of and response to drug shortages.
-
EMA regulation and response to drug shortages
PharmaSources/zhulikou431
June 12, 2023
The EMA has established an agency called the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) to address drug shortages.
-
Regulation and response to drug shortages in the U.S.
PharmaSources/zhulikou431
June 12, 2023
Drug shortages have been a global issue, and the U.S. has been experiencing drug shortages for many years, with more than 100 drug shortages identified in the country each year.
-
The National Healthcare Security Administration announced a price reduction for hydrocortisone acetate tablets
PharmaSources/Laoxue
June 08, 2023
The price is back to the level of about two years ago, and the result is not to stop taking the drug.
-
Long-acting Aripiprazole for Injection Developed by Otsuka Pharmaceutical Gain Approval in China
Caicai/PharmaSources
June 06, 2023
On May 23, the NMPA official website revealed that Aripiprazole (Aripiprazole long-acting intramuscular injection) developed by Otsuka Pharmaceutical to treat schizophrenia was approved for marketing.
-
Innovative Drug HER2 ADC Rejected for Marketing, Stricter FDA Review May be Normal in the Future
Xiaobin/PharmaSources
June 06, 2023
The FDA's rejection of the marketing of SYD985 is just the beginning, and with the rising enthusiasm for the R&D of ADCs, the standards of subsequent review by the FDA of the popular target ADCs will be inevitably raised.
-
China's PI3K Inhibitors Have Made New Progress Since the Approval of Bayer's Copanlisib - Chiatai Tianqing's TQ-B3525 Is Proposed to Be Included in the Priority Review
Dopine/PharmaSources
June 06, 2023
China's PI3K inhibitors have made new progress since the approval of Bayer's Copanlisib - Chiatai Tianqing's TQ-B3525 is proposed to be included in the priority review.
-
More ADCs made in China, Led by Kelun Pharmaceutical, Expanding into the World Market with a Total Transaction Amount of over USD 20 billion
Yi/PharmaSources
June 06, 2023
More ADCs made in China, led by Kelun Pharmaceutical, expanding into the world market with a total transaction amount of over USD 20 billion.
-
Demand for Antipyretic Drug Strikes Again, Restarting the Battle of iBuprofen
Lao Xue/PharmaSources
May 29, 2023
Ibuprofen APIs and preparations are once again experiencing sales growth due to the recurrence of COVID-19 after the previous boom of antipyretic drug.
-
Nanjing Chiatai Tianqing Roxadustat Generic Drug Applied for Production
Yi/PharmaSources
May 29, 2023
In May 2023, the CDE announced the acceptance of eight generic drug marketing applications for Roxadustat from: Nanjing Chiatai Tianqing, Wanbangde Pharmaceutical, Shanxiang Pharmaceutical, Chengdu Brilliant.